0 143

Cited 2 times in

ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이재승-
dc.contributor.author이혜원-
dc.date.accessioned2024-02-15T06:30:55Z-
dc.date.available2024-02-15T06:30:55Z-
dc.date.issued2023-08-
dc.identifier.issn1542-3565-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/197940-
dc.description.abstractBackground & aims: We investigated whether baseline and on-treatment alanine aminotransferase (ALT) levels during entecavir (ETV) therapy are associated with achieving subcirrhotic liver stiffness (LS) and hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related cirrhosis. Methods: We analyzed data from 347 treatment-naïve patients with HBV-related cirrhosis, who started ETV between 2006 and 2011 and were followed up for >5 years without developing HCC. The study outcomes were achieving subcirrhotic LS at 5 years of ETV, and risk of HCC development beyond 5 years of ETV. Subcirrhotic LS was defined as <12 kPa by transient elastography. Results: After 5 years of ETV, 227 (65.4%) patients achieved subcirrhotic LS. During a median follow-up of 9.2 years, 49 (14.1%) patients developed HCC beyond 5 years of ETV. ALT levels at baseline, at 1 year of ETV therapy, and 5 years of ETV therapy were not associated with the probability of achieving subcirrhotic LS at 5 years of ETV therapy or risk of HCC development beyond 5 years of ETV therapy (all P > .05). Patients achieving subcirrhotic LS at 5 years of ETV therapy had significantly lower risk of HCC development than those who did not (adjusted hazard ratio, 0.33; 95% confidence interval, 0.17-0.64; P = .001). Conclusions: Baseline and on-treatment ALT levels were not associated with achieving subcirrhotic LS at 5 years of ETV therapy or with risk of HCC development beyond 5 years of ETV therapy in patients with HBV-related cirrhosis. Achieving subcirrhotic LS at 5 years of ETV therapy was independently associated with lower risk of HCC development beyond 5 years of ETV therapy.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherW.B. Saunders-
dc.relation.isPartOfCLINICAL GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents-
dc.subject.MESHCarcinoma, Hepatocellular* / complications-
dc.subject.MESHHepatitis B virus-
dc.subject.MESHHepatitis B, Chronic* / complications-
dc.subject.MESHHepatitis B, Chronic* / drug therapy-
dc.subject.MESHHepatitis B, Chronic* / pathology-
dc.subject.MESHHumans-
dc.subject.MESHLiver Cirrhosis / complications-
dc.subject.MESHLiver Cirrhosis / drug therapy-
dc.subject.MESHLiver Neoplasms* / complications-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Outcome-
dc.titleALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMi Na Kim-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorSe Young Jang-
dc.contributor.googleauthorWon Young Tak-
dc.contributor.googleauthorYoung-Oh Kweon-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.1016/j.cgh.2022.10.035-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA05963-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ02981-
dc.identifier.eissn1542-7714-
dc.identifier.pmid36375797-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1542356522010503-
dc.subject.keywordAlanine Aminotransferase-
dc.subject.keywordChronic Hepatitis B-
dc.subject.keywordCirrhosis-
dc.subject.keywordHepatocellular Carcinoma-
dc.subject.keywordSubcirrhotic Liver Stiffness-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이재승-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume21-
dc.citation.number9-
dc.citation.startPage2278-
dc.citation.endPage2287-
dc.identifier.bibliographicCitationCLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.21(9) : 2278-2287, 2023-08-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.